Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cleveland Research Downgrades Okta to Neutral

Cleveland Research Downgrades Okta to Neutral

Cleveland Research analyst Ben Bollin downgrades Okta (NASDAQ:OKTA) from Buy to Neutral.

byBenzinga Newsdesk

September 23, 2022

1 minute read

Cleveland Research analyst Ben Bollin downgrades Okta (NASDAQ:OKTA) from Buy to Neutral.

Goldman Sachs Maintains Neutral on Xos, Lowers Price Target to $2.4

By Benzinga Newsdesk

November 14, 11:05 AM

Goldman Sachs analyst Jerry Revich maintains Xos (NASDAQ:XOS) with a Neutral and lowers the price target from $2.8 to $2.4.

XOS

Piper Sandler Maintains Overweight on Twilio, Lowers Price Target to $122

By Benzinga Newsdesk

August 5, 8:26 AM

Piper Sandler analyst Brent Bracelin maintains Twilio (NYSE:TWLO) with a Overweight and lowers the price target from $132 to $122.

TWLO

Mizuho Maintains Buy on NVIDIA, Lowers Price Target to $205

By Benzinga Newsdesk

September 15, 7:24 AM

Mizuho analyst Vijay Rakesh maintains NVIDIA (NASDAQ:NVDA) with a Buy and lowers the price target from $225 to $205.

NVDA

Physicians Realty Trust Q3 FFO $0.26 Beats $0.13 Estimate, Sales $131.50M Beat $131.43M Estimate

By Benzinga Newsdesk

November 3, 7:51 AM

Physicians Realty Trust (NYSE:DOC) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.13 by 100 percent. This is unchanged from the same period last year. The company reported

DOC

Cleveland Research Downgrades Okta to Neutral

Related Posts

Goldman Sachs Maintains Neutral on Xos, Lowers Price Target to $2.4

Piper Sandler Maintains Overweight on Twilio, Lowers Price Target to $122

Mizuho Maintains Buy on NVIDIA, Lowers Price Target to $205

Physicians Realty Trust Q3 FFO $0.26 Beats $0.13 Estimate, Sales $131.50M Beat $131.43M Estimate